451 related articles for article (PubMed ID: 15183535)
21. p53 codon 72 polymorphism as a risk factor in the development of breast cancer.
Papadakis EN; Dokianakis DN; Spandidos DA
Mol Cell Biol Res Commun; 2000 Jun; 3(6):389-92. PubMed ID: 11032762
[TBL] [Abstract][Full Text] [Related]
22. P53 codon 72 polymorphism in breast cancer.
Buyru N; Tigli H; Dalay N
Oncol Rep; 2003; 10(3):711-4. PubMed ID: 12684648
[TBL] [Abstract][Full Text] [Related]
23. TGFbeta1 (Leu10Pro), p53 (Arg72Pro) can predict for increased risk for breast cancer in south Indian women and TGFbeta1 Pro (Leu10Pro) allele predicts response to neo-adjuvant chemo-radiotherapy.
Rajkumar T; Samson M; Rama R; Sridevi V; Mahji U; Swaminathan R; Nancy NK
Breast Cancer Res Treat; 2008 Nov; 112(1):81-7. PubMed ID: 18058229
[TBL] [Abstract][Full Text] [Related]
24. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women.
Bhattacharya P; Sengupta S
Gynecol Oncol; 2005 Oct; 99(1):176-82. PubMed ID: 16054204
[TBL] [Abstract][Full Text] [Related]
25. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer.
Madeleine MM; Shera K; Schwartz SM; Daling JR; Galloway DA; Wipf GC; Carter JJ; McKnight B; McDougall JK
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):225-7. PubMed ID: 10698487
[TBL] [Abstract][Full Text] [Related]
26. Germline polymorphism of p53 codon 72 in gynecological cancer.
Ueda M; Terai Y; Kanda K; Kanemura M; Takehara M; Yamaguchi H; Nishiyama K; Yasuda M; Ueki M
Gynecol Oncol; 2006 Jan; 100(1):173-8. PubMed ID: 16168468
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and spectrum of p53 mutations associated with smoking in breast cancer.
Conway K; Edmiston SN; Cui L; Drouin SS; Pang J; He M; Tse CK; Geradts J; Dressler L; Liu ET; Millikan R; Newman B
Cancer Res; 2002 Apr; 62(7):1987-95. PubMed ID: 11929815
[TBL] [Abstract][Full Text] [Related]
28. Association of breast cancer risk with a common functional polymorphism (Asp327Asn) in the sex hormone-binding globulin gene.
Cui Y; Shu XO; Cai Q; Jin F; Cheng JR; Cai H; Gao YT; Zheng W
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1096-101. PubMed ID: 15894658
[TBL] [Abstract][Full Text] [Related]
29. Correlation of the mutation of p53 gene and the polymorphism at codon 72 in smoking-related non-small cell lung cancer patients.
Murata M; Tagawa M; Kimura H; Kakisawa K; Shirasawa H; Fujisawa T
Int J Oncol; 1998 Mar; 12(3):577-81. PubMed ID: 9472095
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the frequency of TP53 gene codon 72 polymorphisms in Iranian patients with endometrial cancer.
Ghasemi N; Karimi-Zarchi M; Mortazavi-Zadeh MR; Atash-Afza A
Cancer Genet Cytogenet; 2010 Jan; 196(2):167-70. PubMed ID: 20082853
[TBL] [Abstract][Full Text] [Related]
31. p53 codon 72 polymorphism does not affect the risk of cervical cancer in patients from northern Italy.
Tenti P; Vesentini N; Rondo Spaudo M; Zappatore R; Migliora P; Carnevali L; Ranzani GN
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):435-8. PubMed ID: 10794489
[TBL] [Abstract][Full Text] [Related]
32. p53 gene mutations and codon 72 polymorphism in ovarian carcinoma patients from Serbia.
Malisic E; Jankovic R; Slavkovic D; Milovic-Kovacevic M; Radulovic S
J BUON; 2010; 15(1):101-6. PubMed ID: 20414935
[TBL] [Abstract][Full Text] [Related]
33. Ethnicity determines association of p53Arg72Pro alleles with cervical cancer in China.
Zheng XZ; Yang AQ; Pan XL; Zheng LL; Wang XL; Zhou QY; Li XM; Yan LH; Zhang B; Li HA; Jiang JF
Eur J Cancer Prev; 2008 Oct; 17(5):460-6. PubMed ID: 18714189
[TBL] [Abstract][Full Text] [Related]
34. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia.
Zúbor P; Vojvodová A; Danko J; Kajo K; Szunyogh N; Lasabová Z; Biringer K; Visnovský J; Dókus K; Galajda P; Plank L
Neoplasma; 2006; 53(1):49-55. PubMed ID: 16416013
[TBL] [Abstract][Full Text] [Related]
35. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women.
Khadang B; Fattahi MJ; Talei A; Dehaghani AS; Ghaderi A
Cancer Genet Cytogenet; 2007 Feb; 173(1):38-42. PubMed ID: 17284368
[TBL] [Abstract][Full Text] [Related]
36. p53 haplotype determination in breast cancer.
Weston A; Pan CF; Ksieski HB; Wallenstein S; Berkowitz GS; Tartter PI; Bleiweiss IJ; Brower ST; Senie RT; Wolff MS
Cancer Epidemiol Biomarkers Prev; 1997 Feb; 6(2):105-12. PubMed ID: 9037561
[TBL] [Abstract][Full Text] [Related]
37. The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian women.
Spurdle AB; Hopper JL; Chen X; Dite GS; McCredie MR; Giles GG; Venter DJ; Southey MC; Purdie DM; Chenevix-Trench G
Cancer Epidemiol Biomarkers Prev; 2001 Dec; 10(12):1287-93. PubMed ID: 11751447
[TBL] [Abstract][Full Text] [Related]
38. Association of TP53 codon 72 polymorphism with cervical cancer risk in Chinese women.
Jiang P; Liu J; Zeng X; Li W; Tang J
Cancer Genet Cytogenet; 2010 Mar; 197(2):174-8. PubMed ID: 20193851
[TBL] [Abstract][Full Text] [Related]
39. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency.
Govan VA; Loubser S; Saleh D; Hoffman M; Williamson AL
Int J Immunogenet; 2007 Jun; 34(3):213-7. PubMed ID: 17504512
[TBL] [Abstract][Full Text] [Related]
40. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
